Gil Efron News Today

26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC) based on preliminary interim dataProlongation of

Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study

NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in...

NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 13, 2024 --  Purple Biotech Ltd. , a clinical-stage company developing first-in-class therapies...

REHOVOT, Israel, Feb. 01, 2024 -- Purple Biotech Ltd. , a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune...

Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company’s Chief...

This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 --  Purple Biotech Ltd. , a clinical-stage company...

Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients’ Enrollment in the Phase 2 Randomized CM24...

REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported new biomarker data for its lead oncology drug, CM24, a first-in-class anti-CEACAM1 monoclonal antibody. Data were presented at the American Association for Cancer Resear...

Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab;  2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219...